<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479320</url>
  </required_header>
  <id_info>
    <org_study_id>IRC/1078/017</org_study_id>
    <nct_id>NCT03479320</nct_id>
  </id_info>
  <brief_title>Usefulness of Lidocaine in Oral and Maxillofacial Surgeries Under General Anesthesia for Pain Control After Operation</brief_title>
  <official_title>Efficacy of Perioperative Intravenous Lidocaine Infusion on Postoperative Analgesia in Patients Undergoing Oral and Maxillofacial Surgeries Under General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B.P. Koirala Institute of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B.P. Koirala Institute of Health Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized double blinded clinical study conducted in patients undergoing oral
      and maxillofacial surgery under general anesthesia. Lidocaine group will receive intravenous
      bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the
      completion of surgery.Normal saline group will receive same amount of intravenous normal
      saline .The primary outcome will be postoperative pain using the NRS scale during first 24
      hours and time to first analgesic request
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Numeric Rating Scale(NRS)</measure>
    <time_frame>24 hours</time_frame>
    <description>Pain at rest and with cough or movement using the NRS scale, which ranges from 0 to 10; where 0 refers to no pain and 10 refers to most severe pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total opioid consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Total morphine or morphine equivalent in milligram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first analgesic request</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to first analgesic (ketorolac) request (time counted after skin closure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of patients with light headedness, sedation, nausea, vomiting will be documented</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Lidocaine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lidocaine group will receive intravenous bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the completion of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>They will receive the same volume of 0.9% of normal saline as calculated for the experimental group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Postoperative analgesic effects will be compared between lidocaine and normal saline group</description>
    <arm_group_label>Lidocaine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Postoperative anlagesic requirements will be calculated and compared with experimental group</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients 18-60 years of age

          -  Patients of ASA (American Society of Anesthesiologists) Class I or Class II (I-
             healthy with no systemic disease, II- mild systemic disease with no functional
             limitation) who require oral and maxillofacial surgeries under general anesthesia

        Exclusion Criteria:

          -  Refusal to give consent.

          -  Hypersensitivity or allergy to the study medication.

          -  ASA physical status III or more.

          -  Subjects with known severe hepatic or renal dysfunction or cardiac dysrhythmia or
             atrioventricular block.

          -  History of taking opioids or antiarrhythmic drugs within 1 week of surgery.

          -  History of drug or alcohol abuse

          -  History of psychiatric disorders.

          -  Patients requiring emergency surgery.

          -  Patients unable to comprehend pain assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Kr Mahato, BDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>BP Koirala Institute of health sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vivek Kr Mahato, BDS</last_name>
    <phone>9804338217</phone>
    <email>vvkmahato@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>B. P. Koirala Institute of Health Sciences</name>
      <address>
        <city>Dharān Bāzār</city>
        <zip>34464</zip>
        <country>Nepal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Kr Mahato</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>B.P. Koirala Institute of Health Sciences</investigator_affiliation>
    <investigator_full_name>Dr Vivek Kumar Mahato</investigator_full_name>
    <investigator_title>Post graduate resident in Department of Oral and Maxillofacial Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

